Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

Led by Dr. Jeremy Pettus, researchers at UC San Diego are investigating liver-targeted insulin in type 1 diabetes. Explore how this novel insulin could significantly...
People with diabetes are at higher risk for health issues like chronic kidney disease, diabetic macular edema, and liver disease. Here are clinical trials studying ways...
Orforglipron, Eli Lilly's once-daily oral GLP-1 receptor agonist, is being studied in ongoing clinical trials for obesity and type 2 diabetes. Data shows A1C reductions...
Advances in blood glucose management, weight loss, and heart health are at the forefront of type 2 diabetes research. Here are some exciting new clinical trials you can...
The FINE-ONE trial by Bayer investigates Kerendia's effectiveness in preventing kidney disease progression in people with type 1 diabetes. This pivotal trial could...
Novo Nordisk is set to discontinue Levemir, a key long-acting insulin, by the end of 2024 due to manufacturing priorities and better alternatives, impacting supply and...
FDA approves Zepbound for obesity management alongside diet and exercise. A promising new option for weight control, it's the second once-weekly injectable after Wegovy...
Explore the link between obesity, diabetes, and breast cancer risk. Learn how treatments like bariatric surgery and medications can reduce this risk and aid in diabetes...
In case you missed them, here are our top stories from October 2023 that cover upcoming therapies, groundbreaking research, and more.
Join a study investigating BMF-219, a menin inhibitor that could stimulate healthy beta cell regeneration and potentially slow diabetes progression.
Lilly’s SURMOUNT-4 trial shows that Mounjaro (tirzepatide) offers remarkable weight loss in patients with a BMI of over 30. Full SURMOUNT-3 trial results highlighted the...
This trial is investigating a new oral medication, INV-202, which is designed to improve regulation in the kidney, liver, and pancreas.
Data presented at EASD 2023 reveals orforglipron's potential in type 2 diabetes management. The new oral GLP-1 medication demonstrated significant reductions for A1C and...
People with type 1 diabetes face higher kidney risks, yet treatments approved for type 2 aren't FDA approved for them due to clinical trial gaps. The EASD 2023 panel...
Survodutide, a GLP-1/glucagon dual receptor agonist, shows promising weight loss results in a clinical trial. The injectable medication, developed by Zealand and...
At the 59th European Association for the Study of Diabetes in Germany, an expert panel discussed the tremendous cardiovascular health benefits of limiting body weight...
Tirzepatide (sold as Mounjaro) is more effective than semaglutide (Ozempic) for both blood glucose control and weight loss, according to a new analysis.
The newest study of once-weekly insulins showed that insulin icodec led to similar reductions in A1C and similar time in range compared to once-daily Tresiba (degludec).
The FDA is cautioning people that the diabetes medication Ozempic – commonly prescribed off-label for weight loss – may be linked to a rare but severe side effect.
Here are our top stories from September 2023. This month’s best stories cover a wide variety of topics like upcoming therapies, new research findings, and more.

Pages